Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Differential effects of estrogen receptor beta isoforms on glioblastoma progression.

Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner AJ, Vadlamudi RK.

Cancer Res. 2018 Apr 16. pii: canres.3470.2017. doi: 10.1158/0008-5472.CAN-17-3470. [Epub ahead of print]

PMID:
29661831
2.

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.

3.

Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR.

Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.

4.

PELP1: a key mediator of oestrogen signalling and actions in the brain.

Thakkar R, Sareddy GR, Zhang Q, Wang R, Vadlamudi RK, Brann D.

J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12484. Review.

PMID:
28485080
5.

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.

Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK.

Oncogene. 2017 Apr 27;36(17):2423-2434. doi: 10.1038/onc.2016.395. Epub 2016 Nov 28.

PMID:
27893719
6.

Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer.

Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R.

Oncotarget. 2016 Jul 5;7(27):42585-42597. doi: 10.18632/oncotarget.10018.

7.

Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.

Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2016 Apr 29;6:24185. doi: 10.1038/srep24185.

8.

PELP1: Structure, biological function and clinical significance.

Sareddy GR, Vadlamudi RK.

Gene. 2016 Jul 1;585(1):128-134. doi: 10.1016/j.gene.2016.03.017. Epub 2016 Mar 18. Review.

9.

Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain.

Sareddy GR, Zhang Q, Wang R, Scott E, Zou Y, O'Connor JC, Chen Y, Dong Y, Vadlamudi RK, Brann D.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):E6673-82. doi: 10.1073/pnas.1516729112. Epub 2015 Nov 16.

10.

Cancer therapy using natural ligands that target estrogen receptor beta.

Sareddy GR, Vadlamudi RK.

Chin J Nat Med. 2015 Nov;13(11):801-807. doi: 10.1016/S1875-5364(15)30083-2. Review.

11.

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK.

Breast Cancer Res Treat. 2015 Apr;150(3):487-99. doi: 10.1007/s10549-015-3339-x. Epub 2015 Mar 19.

12.

The social network of PELP1 and its implications in breast and prostate cancers.

Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV.

Endocr Relat Cancer. 2014 Aug;21(4):T79-86. doi: 10.1530/ERC-13-0502. Epub 2014 May 23. Review.

13.

Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK.

Cell Death Differ. 2014 Sep;21(9):1409-18. doi: 10.1038/cdd.2014.55. Epub 2014 May 2.

14.

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Gonugunta VK, Sareddy GR, Krishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2014 Jun;13(6):1578-88. doi: 10.1158/1535-7163.MCT-13-0877. Epub 2014 Mar 31.

15.

Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.

Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, Brann DW.

Mol Cell Endocrinol. 2014 May 25;389(1-2):84-91. doi: 10.1016/j.mce.2013.12.019. Epub 2014 Feb 6.

16.

Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells.

Sareddy GR, Kesanakurti D, Kirti PB, Babu PP.

Neurochem Res. 2013 Nov;38(11):2313-22. doi: 10.1007/s11064-013-1142-9. Epub 2013 Sep 8.

PMID:
24013885
17.

KDM1 is a novel therapeutic target for the treatment of gliomas.

Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK.

Oncotarget. 2013 Jan;4(1):18-28.

18.

Therapeutic significance of estrogen receptor β agonists in gliomas.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21.

19.

Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas.

Sareddy GR, Geeviman K, Panigrahi M, Challa S, Mahadevan A, Babu PP.

Neurochem Res. 2012 Jan;37(1):96-104. doi: 10.1007/s11064-011-0586-z. Epub 2011 Sep 16.

PMID:
21922255
20.

The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.

Sareddy GR, Geeviman K, Ramulu C, Babu PP.

J Neurooncol. 2012 Jan;106(1):99-109. doi: 10.1007/s11060-011-0662-x. Epub 2011 Aug 17.

PMID:
21847707
21.

Regulation of rDNA transcription by proto-oncogene PELP1.

Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK.

PLoS One. 2011;6(6):e21095. doi: 10.1371/journal.pone.0021095. Epub 2011 Jun 13.

22.

Protective efficacy of natansnin, a dibenzoyl glycoside from Salvinia natans against CCl4 induced oxidative stress and cellular degeneration in rat liver.

Srilaxmi P, Sareddy GR, Kavi Kishor PB, Setty OH, Babu PP.

BMC Pharmacol. 2010 Oct 12;10:13. doi: 10.1186/1471-2210-10-13.

23.

Mustard NPR1, a mammalian IkappaB homologue inhibits NF-kappaB activation in human GBM cell lines.

Kesanakurti D, Sareddy GR, Babu PP, Kirti PB.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):427-33. doi: 10.1016/j.bbrc.2009.09.046. Epub 2009 Sep 17.

PMID:
19766095
24.

Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas.

Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP.

Neurochem Int. 2009 Sep;55(5):307-17. doi: 10.1016/j.neuint.2009.03.016. Epub 2009 Apr 5.

PMID:
19576519
25.

Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure.

Sareddy GR, Challa S, Panigrahi M, Babu PP.

Neurochem Res. 2009 Jul;34(7):1278-88. doi: 10.1007/s11064-008-9906-3. Epub 2009 Jan 16.

PMID:
19148749

Supplemental Content

Loading ...
Support Center